340B Program Changes Could Shift Prescribing Towards Lower Cost Biosimilars

Hospitals often earn large spreads on high-volume branded drugs bought via 340B. Reforms may make hospitals more price-sensitive, raisin uptake of lower-cost biosimilars.
By Published On: Agosto 10, 2026Categories: DesignCommenti disabilitati su 340B Program Changes Could Shift Prescribing Towards Lower Cost Biosimilars

Share This Story, Choose Your Platform!

About the author : admin